People · Operator

Gregory Jensen

Named in public records as an officer, director or promoter · active 2015–2022 · Other Technology, Other

2
Companies
3
Filings
$27.2M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Toma Biosciences, Inc.Other TechnologySeries A$26.6M$330.0M2015
Novusterra IncOtherPre-Seed$567K$2.0M2022
Operator network

Gregory Jensen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

PAUL CONLEY · 17 companies · 1 sharedPAUL CONLEYWolfgang Daum · 5 companies · 1 sharedWolfgang DaumBrian Clevinger · 4 companies · 1 sharedBrian ClevingerJOHN STEUART · 3 companies · 1 sharedJOHN STEUARTHanlee P. Ji · 1 companies · 1 sharedHanlee P. JiLaurence Marton · 1 companies · 1 sharedLaurence MartonLincoln Nadauld · 1 companies · 1 sharedLincoln NadauldMike Lucero · 1 companies · 1 sharedMike LuceroMark LaVerghetta · 3 companies · 1 sharedMark LaVerghettaByron Price · 2 companies · 1 sharedByron PriceEugene Nichols · 1 companies · 1 sharedEugene NicholsGoran Antic · 1 companies · 1 sharedGoran AnticIndrajith Andrew Weeraratne · 1 companies · 1 sharedIndrajith Andrew …Toma Biosciences, Inc. · $26.6M raisedToma Biosciences, Inc.Novusterra Inc · $0.6M raisedNovusterra IncGregory JensenGJ
Gregory Jensen Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Gregory Jensen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
PAUL CONLEY117
Wolfgang Daum15
Brian Clevinger14
Mark LaVerghetta13
JOHN STEUART13
Byron Price12
Eugene Nichols11
Indrajith Andrew Weeraratne11
Lincoln Nadauld11
Laurence Marton11
Mike Lucero11
Hanlee P. Ji11
Goran Antic11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.